The hypertension optimal treatment study: What did it give us?

Current Hypertension Reports

Volumn 1, Issue 4, 1999, Pages 337-341

  Bryg, Robert J ^a   Graettinger, William F ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT;

AGED; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHY; HEART INFARCTION; HUMAN; HYPERTENSION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; ASPIRIN; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; DIABETIC ANGIOPATHIES; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0033170779     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0043-4     Document Type: Article

References (30)

1. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects o intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351: 1755-1762.
2. Hansson L, Zanchetti A: The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability with special reference to age and gender Blood Press 1995, 4: 313-319.
3. Hansson L, Zanchetti A: The Hypertension Optimal Treatment (HOT) study: patient characteristics: randomization, risk profile and early blood pressure results. Blood Press 1994, 3: 322-327.
4. Hansson L: The Hypertension Optimal Treatment Study (The HOT Study). Blood Press 1993, 2: 62-68.
5. Wiklund I, Halling K, Ryden-Bergsten T, et al.: Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997, 6: 357-364.
6. Hansson L, Zanchetti A: The Hypertension Optimal Treatment (HOT) study: 24 month data on blood pressure and tolerability. Blood Press 1997, 6: 313-317.
7. Julius S: The Hypertension Optimal Treatment (HOT) Study in the United States. Am J Hypertens 1996, 9:41S-44S.
8. Chalmers J: The HOT Study: design and cost of major blood pressure trials. Blood Press 1994, 3: 276-278.
9. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension - Final results of the Systolic Hyperten sion in the Elderly Program. JAMA 1991, 265: 3255-3264
10. Graettinger WF, Weber MA: The Hypertension Syndrome: more than increased blood pressure. Modern Medicine 1992, 60: 118-126.
11. Cruickshank JM, Thorp JM, Zacharias FJ: Benefits and potential harm of lowering high blood pressure. Lancet 1987, i: 581-584.
12. Alderman MH, Ooi WL, Madhavan S, et al.: Treatment induced blood pressure reduction and the risk of myocardial infarction. JAMA 1989, 262: 920-924.
13. Mancia G, Sega R, Milesi C, et al.: Blood pressure control in the hypertensive population. Lancet 1997, 349: 454-457.
14. Dahlof B, Lindholm LH, Hansson L, et al.: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338: 1281-1285.
15. Hansson L: How far should blood pressure be lowered? What is the Role of the J-curve? Am J Hypertens 1990, 3: 726-729.
16. Hansson L: The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens 1996, 14: 537-544.
17. Steering committee of the Physicians Health Study Research Group: Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med 1989, 321: 129-135.
18. Juul-Moller S, Edvardsson N, Jahnmatz B, et al.: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992, 340: 1421-1425.
19. The SALT collaborative group: Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991, 338: 1345-1349.
20. Hansson L, Hedner T, Dahlof B: Prospective, randomized, open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992, 1: 113-119.
21. Bryg RJ, Johns JP, Bryg DJ: Cardiac and noncardiac mortality in reported studies: how they compare to the population. Can J Cardiol 1997, 13:63B.
22. Bryg RJ, Johns JP, Bryg DJ: Cardiovascular mortality in clinical trials: implications for decision analysis. Med Decis Making 1997, 17:539.
23. Bryg DJ, Bryg RJ: Life Effectiveness analysis: technique for trading clinical life years for societal life-years. Am J Manag Care 1995, 1: 237-244.
24. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333: 1301-1307.
25. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-1389.
26. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 1996, 335: 1001-1009.
27. Kendall MJ, Toescu V: The HOT Study. J Clin Pharm and Ther 1998, 23: 137-139.
28. Chalmers J: Hypertension Optimal Treatment (HOT) study: a brilliant concept, but a qualified success. J Hypertens 1998, 16: 1403-1405.
29. Kaplan N: J-curve not burned off by HOT study. Lancet 1998, 351: 1748-1749.
30. Ibsen H: Intensive blood pressure lowering warranted: results of the HOT study: an epitaph for the J-curve concept in hypertension. J Hum Hypertens 1998, 12: 731-732.